These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 10093499

  • 1. Angiotensin II receptors-antagonists, molecular biology, and signal transduction.
    Jagadeesh G.
    Indian J Exp Biol; 1998 Dec; 36(12):1171-94. PubMed ID: 10093499
    [Abstract] [Full Text] [Related]

  • 2. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
    Aulakh GK, Sodhi RK, Singh M.
    Life Sci; 2007 Aug 02; 81(8):615-39. PubMed ID: 17692338
    [Abstract] [Full Text] [Related]

  • 3. Peptides as targets for antihypertensive drug development.
    Hedner T, Sun X, Junggren IL, Pettersson A, Edvinsson L.
    J Hypertens Suppl; 1992 Dec 02; 10(7):S121-32. PubMed ID: 1291647
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 02; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 5. [Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure].
    Sandmann S, Unger T.
    Drugs; 2002 Oct 02; 62 Spec No 1():43-52. PubMed ID: 12036388
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE, McKinnie JJ, Greenberg SS, Giles TD.
    Prog Cardiovasc Dis; 1999 Oct 02; 41(4):265-300. PubMed ID: 10362349
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin II--receptor subtypes characterization and pathophysiological implications.
    Gulati K, Lall SB.
    Indian J Exp Biol; 1996 Feb 02; 34(2):91-7. PubMed ID: 8641721
    [Abstract] [Full Text] [Related]

  • 8. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA, Wendt C, Saborowski F.
    Fiziol Cheloveka; 2005 Feb 02; 31(6):97-105. PubMed ID: 16366159
    [Abstract] [Full Text] [Related]

  • 9. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor.
    Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE.
    Nature; 1991 May 16; 351(6323):233-6. PubMed ID: 2041570
    [Abstract] [Full Text] [Related]

  • 10. How to explain the differences between renin angiotensin system modulators.
    Levy BI.
    Am J Hypertens; 2005 Sep 16; 18(9 Pt 2):134S-141S. PubMed ID: 16125050
    [Abstract] [Full Text] [Related]

  • 11. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 16; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 12. [AT1 angiotensin receptor inhibition as a new therapeutic possibility].
    Hunyady L, Nagy L.
    Orv Hetil; 1997 Oct 12; 138(41):2583-90. PubMed ID: 9411327
    [Abstract] [Full Text] [Related]

  • 13. The renin-angiotensin-aldosterone system and fibrinolysis.
    Felmeden DC, Lip GY.
    J Renin Angiotensin Aldosterone Syst; 2000 Sep 12; 1(3):240-4. PubMed ID: 11881031
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
    Johnston CI.
    Blood Press Suppl; 2000 Sep 12; 1():9-13. PubMed ID: 11059629
    [Abstract] [Full Text] [Related]

  • 15. [The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].
    Carnovali M.
    Clin Ter; 2001 Sep 12; 152(2):103-6. PubMed ID: 11441521
    [Abstract] [Full Text] [Related]

  • 16. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K.
    Vnitr Lek; 2007 Apr 12; 53(4):364-70. PubMed ID: 17578167
    [Abstract] [Full Text] [Related]

  • 17. Historical development of losartan (DuP 753) and angiotensin II receptor subtypes.
    Wong PC, Timmermans PB.
    Blood Press Suppl; 1996 Apr 12; 3():11-4. PubMed ID: 8973760
    [Abstract] [Full Text] [Related]

  • 18. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH.
    Horm Metab Res; 2005 Apr 12; 37 Suppl 1():4-8. PubMed ID: 15918104
    [Abstract] [Full Text] [Related]

  • 19. [Clinical pharmacology of angiotensin II antagonists].
    Ambrosioni E, Bacchelli S.
    Cardiologia; 1994 Dec 12; 39(12 Suppl 1):401-4. PubMed ID: 7634304
    [Abstract] [Full Text] [Related]

  • 20. Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
    Leary AC, MacDonald TM.
    Int J Clin Pract; 1998 Oct 12; 52(7):475-81. PubMed ID: 10622089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.